Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Body Temperature | 1 | 2022 | 781 | 0.660 |
Why?
|
| Circadian Rhythm | 1 | 2022 | 2576 | 0.370 |
Why?
|
| Keratoplasty, Penetrating | 2 | 2002 | 144 | 0.220 |
Why?
|
| Hyperopia | 1 | 2001 | 41 | 0.190 |
Why?
|
| Epithelium, Corneal | 2 | 2002 | 253 | 0.190 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2001 | 84 | 0.180 |
Why?
|
| Lenses, Intraocular | 1 | 2001 | 139 | 0.170 |
Why?
|
| Myopia | 1 | 2001 | 253 | 0.160 |
Why?
|
| Rest | 1 | 2022 | 918 | 0.150 |
Why?
|
| Light | 1 | 2022 | 1353 | 0.140 |
Why?
|
| Wakefulness | 1 | 2022 | 1265 | 0.130 |
Why?
|
| Corneal Diseases | 1 | 2001 | 542 | 0.120 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 89 | 0.080 |
Why?
|
| Sleep | 1 | 2022 | 4768 | 0.070 |
Why?
|
| Genes, p53 | 1 | 2008 | 712 | 0.070 |
Why?
|
| raf Kinases | 1 | 2006 | 118 | 0.060 |
Why?
|
| Patient Dropouts | 1 | 2007 | 412 | 0.060 |
Why?
|
| Benzenesulfonates | 1 | 2006 | 166 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2008 | 1085 | 0.060 |
Why?
|
| Asbestos | 1 | 2005 | 251 | 0.050 |
Why?
|
| Octreotide | 1 | 2004 | 153 | 0.050 |
Why?
|
| Carcinogens | 1 | 2005 | 452 | 0.050 |
Why?
|
| Thymoma | 1 | 2004 | 188 | 0.050 |
Why?
|
| Fluorophotometry | 1 | 2001 | 40 | 0.050 |
Why?
|
| Thymus Neoplasms | 1 | 2004 | 274 | 0.050 |
Why?
|
| Mathematics | 1 | 2001 | 707 | 0.040 |
Why?
|
| Pleural Neoplasms | 1 | 2005 | 609 | 0.040 |
Why?
|
| Optics and Photonics | 1 | 2001 | 306 | 0.040 |
Why?
|
| Prednisone | 1 | 2004 | 1563 | 0.040 |
Why?
|
| Mesothelioma | 1 | 2005 | 807 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2001 | 15633 | 0.040 |
Why?
|
| Melanoma | 2 | 2008 | 5709 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2005 | 2898 | 0.040 |
Why?
|
| Lung Neoplasms | 3 | 2008 | 13382 | 0.040 |
Why?
|
| Cataract Extraction | 1 | 2001 | 467 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2007 | 11742 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2007 | 2690 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2006 | 5315 | 0.030 |
Why?
|
| Health Status | 2 | 2007 | 4077 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2004 | 1051 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2008 | 3466 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 1520 | 0.030 |
Why?
|
| Tissue Donors | 2 | 2002 | 2332 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2004 | 10090 | 0.030 |
Why?
|
| Pyridines | 1 | 2006 | 2875 | 0.030 |
Why?
|
| Cornea | 1 | 2001 | 1333 | 0.030 |
Why?
|
| Carcinoma | 1 | 2004 | 2330 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2005 | 4486 | 0.020 |
Why?
|
| Humans | 14 | 2022 | 761572 | 0.020 |
Why?
|
| Apoptosis | 1 | 2006 | 9489 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2001 | 3575 | 0.020 |
Why?
|
| Middle Aged | 10 | 2008 | 220920 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2001 | 9646 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2008 | 129 | 0.020 |
Why?
|
| Aged | 9 | 2008 | 169310 | 0.020 |
Why?
|
| Proportional Hazards Models | 3 | 2007 | 12463 | 0.020 |
Why?
|
| Quality of Life | 1 | 2007 | 13367 | 0.020 |
Why?
|
| bcl-Associated Death Protein | 1 | 2006 | 102 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2006 | 173 | 0.020 |
Why?
|
| Vincristine | 1 | 2007 | 1036 | 0.020 |
Why?
|
| Male | 9 | 2008 | 360842 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 39107 | 0.010 |
Why?
|
| Niacinamide | 1 | 2006 | 413 | 0.010 |
Why?
|
| Prevalence | 1 | 2001 | 15732 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2008 | 732 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2008 | 1206 | 0.010 |
Why?
|
| Geography | 1 | 2005 | 656 | 0.010 |
Why?
|
| Adult | 7 | 2008 | 221203 | 0.010 |
Why?
|
| Caspases | 1 | 2006 | 879 | 0.010 |
Why?
|
| Phenylurea Compounds | 1 | 2006 | 529 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2007 | 1642 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 681 | 0.010 |
Why?
|
| Carboplatin | 1 | 2005 | 794 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 2220 | 0.010 |
Why?
|
| Neoplasm Staging | 2 | 2008 | 11121 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 11122 | 0.010 |
Why?
|
| California | 1 | 2005 | 1430 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 1246 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2007 | 2224 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4575 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2006 | 1135 | 0.010 |
Why?
|
| Biometry | 1 | 2003 | 563 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 21017 | 0.010 |
Why?
|
| Female | 8 | 2008 | 392686 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 2281 | 0.010 |
Why?
|
| Mitochondrial Proteins | 1 | 2006 | 976 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2002 | 54426 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2004 | 58986 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 2880 | 0.010 |
Why?
|
| Remission Induction | 1 | 2005 | 2397 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 1406 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2002 | 992 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 3514 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2008 | 2547 | 0.010 |
Why?
|
| Treatment Outcome | 4 | 2008 | 64684 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 6344 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2001 | 41493 | 0.010 |
Why?
|
| Risk Factors | 2 | 2005 | 74213 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2005 | 1732 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2008 | 4001 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 5485 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2006 | 2910 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2006 | 2639 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 2872 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2005 | 2094 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 8633 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 2005 | 1813 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 8321 | 0.010 |
Why?
|
| Weight Loss | 1 | 2006 | 2684 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2004 | 2469 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2004 | 6815 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 5247 | 0.010 |
Why?
|
| Forecasting | 1 | 2002 | 2928 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 8528 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 7396 | 0.010 |
Why?
|
| Mitochondria | 1 | 2006 | 3624 | 0.010 |
Why?
|
| Adolescent | 1 | 2001 | 88324 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 8552 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12059 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2008 | 7858 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 12725 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 10212 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 13255 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 16986 | 0.010 |
Why?
|
| Registries | 1 | 2005 | 8224 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2003 | 5079 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 5369 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2005 | 22176 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 15266 | 0.000 |
Why?
|
| Incidence | 1 | 2005 | 21355 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 2003 | 5146 | 0.000 |
Why?
|
| Age Factors | 1 | 2002 | 18398 | 0.000 |
Why?
|
| Time Factors | 1 | 2003 | 39970 | 0.000 |
Why?
|
| Prognosis | 1 | 2002 | 29629 | 0.000 |
Why?
|
| United States | 1 | 2004 | 72335 | 0.000 |
Why?
|
Concepts
(135)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(13)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_